Int'l Center for Indigenous Phytotherapy Studies--TICIPS

描述（由申请人提供）：密苏里大学哥伦比亚分校（MU）将与南非西开普大学（UWC）和圣路易斯密苏里植物园（MOBOT）合作成立国际本土植物疗法研究中心（icips）。MU在医疗保健质量改善和生物医学科学方面拥有杰出的研究和教育项目，包括MU植物营养素和植物化学研究中心。UWC拥有杰出的CAM研究和教育项目，特别是在药用植物方面，并与南非使用传统治疗师和南非政府建立了广泛的联系。MOBOT是研究非洲植物群的北美中心。在大学和UWC长达17年的合作关系的基础上，为规划工作寻求资金，以确定itips的使命、愿景和战略计划；发展行政基础设施，以支持合作研究和联合教育活动；评估建立一个综合性的国际补充和替代医学研究中心所需的资源和需求。在第一阶段，将建立健全的行政结构和政策，以确保符合两国关于进行人类和动物研究、财务披露、利益冲突和知识产权的规定。这些飞行员将用于展示合作伙伴的能力，并启动实现NCCAM目标的研究和培训工作。试点1将对Sutherlandia frutscens进行一期临床试验，Sutherlandia frutscens是一种用于阻止艾滋病患者消瘦的草药。试点2将研究紫土巴格菌作为本土植物治疗念珠菌病。试验3将评估萱草植物治疗前列腺增生和癌症的效果。这些项目的规划和执行以及行政核心的发展将为国际研究、补充和替代医学中心奠定基础。

DESCRIPTION (provided by applicant): The University of Missouri-Columbia (MU) will form the International Center for Indigenous Phytotherapy Studies (TICIPS) in collaboration with the University of Western Cape, South Africa (UWC) and the Missouri Botanical Garden, St. Louis (MOBOT). MU has outstanding research and educational programs in health care quality improvement and biomedical sciences, including the MU Center for Phytonutrient and Phytochemical Studies. UWC has outstanding CAM research and educational programs, especially in medicinal plants, and extensive ties with South Africans that use traditional healers, and with the South African government. MOBOT is the North American center for research of African flora. Funds are sought for a planning effort, building upon a 17-year relationship between MU and UWC, to define the mission, vision and strategic plan for TICIPS; to develop the administrative infrastructure to support collaborative research studies and joint educational activities; and to assess resources and needs required for the establishment of a comprehensive international center for research on complementary and alternative medicine. During Phase I, sound administrative structures and policies will be established to ensure compliance with both countries' regulations on the conduct of research with human subjects and animal subjects, financial disclosure, conflict of interest and intellectual property rights. The pilots will serve to demonstrate the capabilities of the partners and to initiate research and training efforts that fulfill the goals of NCCAM. Pilot 1 will open a Phase I clinical trial on Sutherlandia frutscens, an herbal used to deter wasting in AIDS patients. Pilot 2 will study Tulbaghia violacea as an indigenous phytotherapy for candidiasis. Pilot 3 will evaluate Hypoxis hemerocallidea phytotherapies for prostate hyperplasia and cancer. Planning and execution of these projects and the development of an administrative core will lay the foundation for an International Center for Research and Complementary and Alternative Medicine.